Lifshitz & Miller LLP Announces Investigation of Cadus Corporation, CYS Investments, Inc., Gener8 Maritime, Inc. KLX Inc., OPKO Health, Inc., Recro Pharma, Inc., Vectren Corporation and Xcerra Corpora

Lifshitz & Miller LLP Announces Investigation of Cadus Corporation, CYS Investments, Inc., Gener8 Maritime, Inc. KLX Inc., OPKO Health, Inc., Recro Pharma, Inc., Vectren Corporation and Xcerra Corporation

PR Newswire

NEW YORK, June 5, 2018 /PRNewswire/ --

Cadus Corporation (KDUS)

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of Cadus to Starfire Holding for $1.61 per share.

If you are a Cadus investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

CYS Investments, Inc. (CYS)

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of CYS to Two Harbors Investment, for $7.79 in cash and 2 shares of Two Harbors per CYS share.

If you are a CYS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Gener8 Maritime, Inc. (GNRT)

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of Gener8 to Euronav for 0.7272 Euronav share.

If you are a Gener8 investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

KLX Inc. (KLXI)

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of KLX to Boeing Company for $63.00 per share.

If you are a KLX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

OPKO Health, Inc. (OPK)

Lifshitz & Miller announces investigation into possible securities laws violations in connection with the issuance of a draft local coverage determination for its 4Kscore test.

If you are an OPKO investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Recro Pharma, Inc. (REPH)

Lifshitz & Miller announces investigation into possible securities laws violations in connection with the announcement that the FDA declined to approve Recro's NDA for IV meoxicam.

If you are a REPH investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Vectren Corporation (VVC)

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of Vectren to CenterPoint Energy for $72.00 per share.

If you are a Vectren investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Xcerra Corporation (XCRA)

Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of Xcerra to Cohu for $9.00 and 0.2109 Cohu shares per share.

If you are an Xcerra investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

ATTORNEY ADVERTISING. © 2018 Lifshitz & Miller LLP.  The law firm responsible for this advertisement is Lifshitz & Miller LLP, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz & Miller LLP
Phone:  516-493-9780 
Facsimile: 516-280-7376
Email: [email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/lifshitz--miller-llp-announces-investigation-of-cadus-corporation-cys-investments-inc-gener8-maritime-inc-klx-inc-opko-health-inc-recro-pharma-inc-vectren-corporation-and-xcerra-corporation-300660458.html

SOURCE Lifshitz & Miller Law Firm

Copyright CNW Group 2018